Sathej Gopalakrishnan
Overview
Explore the profile of Sathej Gopalakrishnan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
379
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Badawi M, Gopalakrishnan S, Engelhardt B, Palenski T, Karol S, Rubnitz J, et al.
Clin Ther
. 2024 Oct;
46(10):759-767.
PMID: 39368878
Purpose: This work aimed to characterize the pharmacokinetics and exposure-response relationships of venetoclax in pediatric patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) to identify venetoclax doses to...
2.
Montalban X, Vermersch P, Arnold D, Bar-Or A, Cree B, Cross A, et al.
Lancet Neurol
. 2024 Sep;
23(11):1119-1132.
PMID: 39307151
Background: Evobrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has shown preliminary efficacy in people with relapsing multiple sclerosis in a phase 2 trial. Here, we aimed to compare the safety...
3.
Klopp-Schulze L, Gopalakrishnan S, Yalkinoglu O, Kuroki Y, Lu H, Goteti K, et al.
Clin Pharmacol Ther
. 2024 Feb;
115(6):1346-1357.
PMID: 38415785
Enpatoran is a novel, highly selective, and potent dual toll-like receptor (TLR)7 and TLR8 inhibitor currently under development for the treatment of autoimmune disorders including systemic lupus erythematosus (SLE), cutaneous...
4.
Gopalakrishnan S, Menon R, Suleiman A, Kater A, Stilgenbauer S, Seymour J, et al.
Hemasphere
. 2023 Nov;
7(12):e983.
PMID: 38026788
No abstract available.
5.
Scheible H, Schieferstein H, Schmidt R, Pusecker K, Gradhand U, Gopalakrishnan S, et al.
Xenobiotica
. 2023 Oct;
53(8-9):547-558.
PMID: 37880944
Evobrutinib is a highly selective, covalent, central nervous system-penetrant Bruton's tyrosine kinase (BTK) inhibitor, currently in Phase III trials for the treatment of relapsing multiple sclerosis. One major circulating metabolite...
6.
Badawi M, Coppola S, Eckert D, Gopalakrishnan S, Engelhardt B, Doelger E, et al.
Hematol Oncol
. 2023 Sep;
42(1):e3222.
PMID: 37740931
Venetoclax, a potent BCL-2 inhibitor, is currently under development for treatment of t(11;14) Multiple myeloma (MM). The objective of this research was to investigate the exposure-response relationships of venetoclax for...
7.
Bolleddula J, Gopalakrishnan S, Hu P, Dong J, Venkatakrishnan K
Clin Transl Sci
. 2022 Jun;
15(9):2075-2095.
PMID: 35722783
N-Nitrosamine (NA) impurities are considered genotoxic and have gained attention due to the recall of several marketed drug products associated with higher-than-permitted limits of these impurities. Rifampicin is an index...
8.
Brackman D, Eckert D, Menon R, Salem A, Potluri J, Smith B, et al.
Hematol Oncol
. 2022 Jan;
40(2):269-279.
PMID: 35043428
This study evaluated venetoclax population pharmacokinetics (popPK) in patients with treatment-naïve acute myeloid leukemia and assessed the relationship between venetoclax exposure and clinical response for venetoclax in combination with either...
9.
Muensterman E, Engelhardt B, Gopalakrishnan S, Anderson J, Mohamed M
Clin Transl Sci
. 2021 Aug;
15(1):267-278.
PMID: 34464029
Upadacitinib is an oral Janus kinase inhibitor approved for the treatment of rheumatoid arthritis (RA) and recently approved by the European Medicines Agency for the treatment of psoriatic arthritis (PsA)....
10.
Mohamed M, Gopalakrishnan S, Teixeira H, Othman A
J Clin Pharmacol
. 2020 Nov;
61(5):628-635.
PMID: 33156550
Upadacitinib is a selective Janus kinase 1 inhibitor that was recently approved for treatment of rheumatoid arthritis and is currently being evaluated for treatment of several other autoimmune diseases, including...